Yüklüyor......
Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned
In the past 3 years, we have witnessed the completion of four randomized phase III studies in neuroendocrine tumors and the approval of two new drugs, everolimus and sunitinib, for the treatment of patients with well-differentiated pancreatic neuroendocrine tumors. These studies demonstrate a shift...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AlphaMed Press
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3662843/ https://ncbi.nlm.nih.gov/pubmed/23615698 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0434 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|